


10/519336

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on July 22, 2005



Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 CFR
§1.825(a) THROUGH (c)
Patent Application
Docket No. G-194US04PCT
Serial No. 10/519,336

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Daniel Cohen, Ilya Chumakov, Marta Blumenfeld, Sanober Shaikh, Marta Palicio-Barron, Hadi Abderrahim, Pascale Grel
Serial No. : 10/519,336
Filed : December 22, 2004
Conf. No. : 9315
For : Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: